» Articles » PMID: 37232739

Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update

Abstract

Liver fibrosis represents one of the greatest challenges in medicine. The fact that it develops with the progression of numerous diseases with high prevalence (NAFLD, viral hepatitis, etc.) makes liver fibrosis an even greater global health problem. Accordingly, it has received much attention from numerous researchers who have developed various in vitro and in vivo models to better understand the mechanisms underlying fibrosis development. All these efforts led to the discovery of numerous agents with antifibrotic properties, with hepatic stellate cells and the extracellular matrix at the center of these pharmacotherapeutic strategies. This review focuses on the current data on numerous in vivo and in vitro models of liver fibrosis and on various pharmacotherapeutic targets in the treatment of liver fibrosis.

Citing Articles

Green Tea Polyphenol (-)-Epicatechin Pretreatment Mitigates Hepatic Steatosis in an In Vitro MASLD Model.

Hefer M, Petrovic A, Roguljic L, Kolaric T, Kizivat T, Wu C Curr Issues Mol Biol. 2024; 46(8):8981-8994.

PMID: 39194748 PMC: 11352320. DOI: 10.3390/cimb46080531.

References
1.
Sandoval A, Maden M . Regeneration in the spiny mouse, Acomys, a new mammalian model. Curr Opin Genet Dev. 2020; 64:31-36. PMC: 9724456. DOI: 10.1016/j.gde.2020.05.019. View

2.
Zhang Y, Huang D, Gao W, Yan J, Zhou W, Hou X . Lack of IL-17 signaling decreases liver fibrosis in murine schistosomiasis japonica. Int Immunol. 2015; 27(7):317-25. DOI: 10.1093/intimm/dxv017. View

3.
Harrison S, Wong V, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z . Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020; 73(1):26-39. DOI: 10.1016/j.jhep.2020.02.027. View

4.
Schuppan D, Afdhal N . Liver cirrhosis. Lancet. 2008; 371(9615):838-51. PMC: 2271178. DOI: 10.1016/S0140-6736(08)60383-9. View

5.
McPherson S, Jarvis H, McGonigle J, Bedlington J, Dean J, Hallsworth K . Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface. BMJ Open Gastroenterol. 2023; 10(1). PMC: 9923258. DOI: 10.1136/bmjgast-2022-001092. View